Prasugrel is a precursor drug. It forms active molecules after metabolism through cytochrome P450 in the liver and binds to platelet P2Y12 receptor to exert anti platelet aggregation activity.
Inhibition of platelet activation and concurrent aggregation by blocking P2Y12 adenosine diphosphate receptor on platelet surface. Antiplatelet drugs are used to prevent platelets from gathering or sticking together. If platelets gather, they can lead to artery blockage and may lead to heart disease or stroke.
This product is used for the treatment of acute coronary syndrome and has a higher and more reliable inhibitory effect on platelet aggregation.